Overview
AVTX market data
Price History
AVTX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$5.84 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.63 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -23,254.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $8.41 – $24.27 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1B · P/B 3.97 · P/S 17,688.81.
Company News
Guggenheim Maintains Buy on Avalo Therapeutics, Lowers Price Target to $48Benzinga · Aug 7, 2026, 5:14 PM
HC Wainwright & Co. Maintains Buy on Avalo Therapeutics, Lowers Price Target to $30Benzinga · Aug 7, 2026, 11:07 AM
Avalo Therapeutics Q2 EPS $(0.83) Misses $(0.58) EstimateBenzinga · Aug 6, 2026, 11:46 AM
Avalo Therapeutics Files Prospectus For Offering Up To 128,189 Common Shares On Behalf Of Selling ShareholdersBenzinga · Jul 28, 2026, 8:48 PM
Leerink Partners Initiates Coverage On Avalo Therapeutics with Outperform Rating, Announces Price Target of $38Benzinga · Jul 6, 2026, 12:15 PM
Avalo Therapeutics to Join the Russell 2000® and Russell 3000® IndexesGlobenewswire Inc · Jun 26, 2026, 11:15 AM
Avalo Therapeutics To Be Added To Small-Cap Russell 2000 Index And Broad-Market Russell 3000 Index, Effective June 26Benzinga · Jun 26, 2026, 11:10 AM
8-K filing — Avalo Therapeutics, Inc. (AVTX)SEC EDGAR · Jun 23, 2026, 11:01 AM
Avalo Therapeutics Advances AVTX-010, Long-Acting Next-Gen Anti-IL-1β mAB With Potential For Development In HS And Additional Inflammatory Disorders; IND Submission Planned For H1 2027Benzinga · Jun 16, 2026, 11:10 AM
This ICU Medical Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For MondayBenzinga · Jun 15, 2026, 1:20 PM